Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $38.57

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year […]

Related Keywords

Melissab Epperly , , Insider Transactions At Zentalis Pharmaceuticals , Decheng Capital , Zentalis Pharmaceuticals Price Performance , Nasdaq , Institutional Investors Weigh In On Zentalis Pharmaceuticals , News Ratings For Zentalis Pharmaceuticals Daily , Vanguard Group Inc , Rafferty Asset Management , Zentalis Pharmaceuticals Inc , Hermes Inc , Analyst Recommendations For Zentalis Pharmaceuticals , Zentalis Pharmaceuticals , Eventide Asset Management , Get Free Report , Marketbeat Ratings , Asset Management , Get Free , Zentalis Pharmaceuticals Daily , Nasdaq Zntl , Zntl , Medical , Ratings , Consensus ,